Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott N Freeman

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cancer Biology & Therapy|December 22, 2004
E2F4 deficiency promotes drug-induced apoptosisYihong Ma, Scott N Freeman, W Douglas Cress
The Journal of Biological Chemistry|November 28, 2007
RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosisScott N Freeman, Yihong Ma, W Douglas Cress
Cell Stem Cell|September 1, 2010
The Orphan Drug Act and the development of stem cell-based products for rare diseasesScott N Freeman, Kathryn A Burke, Menfo A Imoisili, et al.
Pediatrics|February 29, 2012
What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysisChandana Thorat, Kui Xu, Scott N Freeman, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cancer Biology & Therapy|December 22, 2004
E2F4 deficiency promotes drug-induced apoptosisYihong Ma, Scott N Freeman, W Douglas Cress
The Journal of Biological Chemistry|November 28, 2007
RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosisScott N Freeman, Yihong Ma, W Douglas Cress
Cell Stem Cell|September 1, 2010
The Orphan Drug Act and the development of stem cell-based products for rare diseasesScott N Freeman, Kathryn A Burke, Menfo A Imoisili, et al.
Pediatrics|February 29, 2012
What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysisChandana Thorat, Kui Xu, Scott N Freeman, et al.
Pageof 1